Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Burchert

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Bone Marrow Transplantation|November 29, 2016
PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantationJ C Albring, S Inselmann, T Sauer, et al.
Leukemia|January 21, 2006
Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemiaM Ritter, D Kattmann, S Teichler, et al.
Leukemia|May 16, 2015
NFATc1 as a therapeutic target in FLT3-ITD-positive AMLS K Metzelder, C Michel, M von Bonin, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2017
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantationS K Metzelder, T Schroeder, M Lübbert, et al.
Leukemia|April 17, 2012
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responsesS K Metzelder, T Schroeder, A Finck, et al.
Leukemia|February 14, 2015
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IVL Kalmanti, S Saussele, M Lauseker, et al.
Leukemia|January 12, 2017
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLC Schütz, S Inselmann, S Saussele, et al.
Leukemia|January 31, 2018
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLC Schütz, S Inselmann, S Saussele, et al.
Leukemia|June 18, 2026
Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker StudyS Rinaldetti, M Chepeleva, A Hedblom, et al.
Leukemia|August 1, 2015
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter surveyR Zeiser, A Burchert, C Lengerke, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Bone Marrow Transplantation|November 29, 2016
PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantationJ C Albring, S Inselmann, T Sauer, et al.
Leukemia|January 21, 2006
Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemiaM Ritter, D Kattmann, S Teichler, et al.
Leukemia|May 16, 2015
NFATc1 as a therapeutic target in FLT3-ITD-positive AMLS K Metzelder, C Michel, M von Bonin, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2017
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantationS K Metzelder, T Schroeder, M Lübbert, et al.
Leukemia|April 17, 2012
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responsesS K Metzelder, T Schroeder, A Finck, et al.
Leukemia|February 14, 2015
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IVL Kalmanti, S Saussele, M Lauseker, et al.
Leukemia|January 12, 2017
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLC Schütz, S Inselmann, S Saussele, et al.
Leukemia|January 31, 2018
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLC Schütz, S Inselmann, S Saussele, et al.
Leukemia|June 18, 2026
Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker StudyS Rinaldetti, M Chepeleva, A Hedblom, et al.
Leukemia|August 1, 2015
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter surveyR Zeiser, A Burchert, C Lengerke, et al.
Pageof 4